Lexeo Therapeutics, Inc. Common Stock (LXEO) Earnings History
Annual and quarterly earnings data from 2020 to 2024
Loading earnings history...
LXEO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LXEO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 100.0% | -9252.1% | -9063.8% |
| 2021 | 100.0% | -3055.9% | -3055.0% |
| 2020 | 100.0% | -884.9% | -993.8% |
Download Data
Export LXEO earnings history in CSV or JSON format
Free sign-in required to download data
Lexeo Therapeutics, Inc. Common Stock (LXEO) Earnings Overview
As of May 8, 2026, Lexeo Therapeutics, Inc. Common Stock (LXEO) reported trailing twelve-month net income of -$105M, reflecting -24.1% year-over-year growth. The company earned $-1.72 per diluted share over the past four quarters.
Looking at the long-term picture, LXEO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2020.
Lexeo Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCKT (-$223M net income), KRYS ($225M net income, 52.6% margin), SGMO (-$109M net income, -169.4% margin), LXEO has comparable earnings metrics. Compare LXEO vs RCKT →
LXEO Earnings vs Peers
Earnings metrics vs comparable public companies
LXEO Historical Earnings Data (2020–2024)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$98M | -48.1% | -$106M | $-3.09 | - | - |
| 2023 | -$66M | -12.0% | -$69M | $-2.49 | - | - |
| 2022 | -$59M | -17.1% | -$61M | $-2.40 | -9063.8% | -9252.1% |
| 2021 | -$51M | -882.4% | -$51M | $-2.01 | -3055.0% | -3055.9% |
| 2020 | -$5M | - | -$5M | $-0.20 | -993.8% | -884.9% |
See LXEO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LXEO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LXEO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLXEO — Frequently Asked Questions
Quick answers to the most common questions about buying LXEO stock.
Is LXEO growing earnings?
LXEO EPS fell to $-1.72, with earnings declining -24.1%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-105M.
What are LXEO's profit margins?
Lexeo Therapeutics, Inc. Common Stock net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are LXEO's earnings?
LXEO earnings data spans 2020-2024. The declining earnings trend is -24.1% YoY. Historical data enables comparison across business cycles.